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Abstract 
Background and aims:  The involvement of a systemic inflammatory response, as evidenced 
by the Glasgow Prognostic Score (GPS), is associated with weight loss and poor outcome in 
patients with non-small cell lung cancer.  There is good evidence that nutritional and 
functional decline in patients with advanced malignant disease is associated with catabolic 
changes in metabolism.  However, defects in anabolism may also contribute towards 
nutritional decline in patients with cancer.  The aim of the present study was to examine the 
relationship between IGF-1 and IGFBP-3, performance status, mGPS and survival in patients 
with inoperable NSCLC.   
Methods:  56 patients with inoperable NSCLC were studied.  The plasma concentrations of 
IGF-1, IGFBP-3 and leptin were measured using ELISA and RIA.  
Results:  The patients were predominantly male (61%), over 60 years old (80%), with 
advanced (stage III or IV) disease (98%), with a BMI >20 (84%), an ECOG-ps of 0 or 1 
(79%), a haemoglobin (59%) and white cell count (79%) in the reference range.  On follow-
up 43 patients died of their cancer.  On univariate analysis, BMI (p<0.05), Stage (p<0.05), 
ECOG-ps (p<0.05), haemoglobin (p<0.05), white cell count (p<0.05) and mGPS (p<0.05) 
were associated with cancer specific survival.  There was no association between age, sex, 
treatment, IGF-1, IGFBP-3, IGF-1:IGFBP-3 ratio, or leptin and cancer specific survival.  
With an increasing mGPS concentrations of haemoglobin (p<0.005) and IGFBP-3 (p<0.05) 
decreased.  mGPS was not associated with either IGF-1(p>0.20), or leptin (p>0.20).  
Conclusions:  In summary, the results of this study suggest that anabolism (IGF-1 axis) does 
not play a significant role in the relationship between nutritional and functional decline, 
systemic inflammation and poor survival in patients with inoperable NSCLC. 
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Non-standard abbreviations:  GPS: Glasgow prognostic score, IGF-1: Insulin-like growth 
factor-1, IGFBP-3: Insulin-like growth factor binding protein –3, NSCLC: Non-small cell 
lung cancer 
 
Key words:  Insulin-like growth factor-1, IGF-binding protein-3, weight loss, C-reactive 
protein, albumin, non-small cell lung cancer.  
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Introduction 
Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related 
death in the world, responsible for over 600,000 deaths each year1.  In the United Kingdom, 
there are over 30,000 new cases registered per year, with only 7% of these patients alive at 
five years2.  Many patients present with advanced inoperable disease, have cachexia, poor 
performance status and poor survival3. 
 Nutritional and functional decline in cancer patients is associated with disordered 
metabolism, particularly the development of a systemic inflammatory response4,5.  This 
systemic inflammatory involvement, as evidenced by elevated circulating concentrations of 
C-reactive protein and hypoalbuminaemia (Glasgow Prognostic score, GPS), is a normal 
response to an insult which, when prolonged in cancer, becomes detrimental to the patient, 
being associated with cachexia, poor performance status and reduced survival in patients with 
a variety of common solid tumours6-8.  These deleterious consequences have been attributed, 
in part, to the production of inflammatory cytokines, in particular interleukin 1-beta and 
interleukin-69-11, which exert a directly catabolic effect on skeletal muscle and other host 
tissues12-13.  Indeed, Krzystek-Korpacka and colleagues14 recently reported that the GPS was 
associated with increased weight loss and elevated concentrations of IL-1, IL-6, IL-8, TNF-
alpha, VEGF-A and midkine concentrations.  
 However, although defects in anabolism may encourage and maintain this 
deleterious state of catabolism, few studies have addressed the relationship between the 
systemic inflammatory response and anabolic mediators of metabolism in patients with 
advanced cancer15-17.  The insulin-like growth factor-1 (IGF-1) axis is an important regulator 
of anabolism, which may be deregulated in advanced cancer15,18.  The majority of IGF-1 in 
human serum circulates in association with IGF-binding protein-3, which prolongs its half-life 
but reduces its bioactivity.  
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 The aim of the present study was to examine the relationship between IGF-1, 
IGFBP-3, weight loss and the systemic inflammatory response in patients with inoperable 
non-small cell lung cancer. 
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Patients and Methods 
Patients 
Patients presenting to a multidisciplinary oncology clinic at the Royal Infirmary 
between November 2003 and April 2004, with inoperable NSCLC were included in the study.  
All patients had cytologically or histologically confirmed disease and were staged on the basis 
of clinical findings, chest X-ray, and where appropriate, bronchoscopy, liver ultrasound, 
isotope bone scan and computerized tomography of the thorax, according to the American 
Thoracic Society TNM classification.  Patients were excluded if they had any history of 
metabolic or endocrine disorders, or were on oral corticosteroid therapy.  Healthy subjects 
were recruited from a cardiovascular risk factor clinic to form a control group.   
The study was approved by the Ethics Committee of Glasgow Royal Infirmary.  All 
participants were informed of the purpose of the study prior to entry and gave written, 
informed consent.   
 
Methods 
The body mass index (BMI), extent of weight loss and ECOG performance status 
were measured at the time of diagnosis.  A fasting blood sample was taken at the clinic for 
routine laboratory analysis of white cell count and serum concentrations of haemoglobin, C-
reactive protein, albumin and glucose.  The inter- and intra-assay variability in each case was 
less than 10%.  The minimal detectable concentration of C-reactive protein was 6mg/l.  
 A further blood sample was taken, placed immediately on ice and centrifuged at 1000g 
for 15 minutes at 4oC.  The plasma was then frozen at -20oC for batch analysis of circulating 
concentrations of IGF-1 and IGFBP-3.   
All measurements were carried out prior to treatment. 
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The enzyme-linked immunosorbant assay (ELISA) method was employed for 
quantification of IGF-1 and IGFBP-3.  IGF-1 concentrations were measured using a 
commercial Octeia IGF-1 kit (Immunodiagnostic Systems, Boldon, UK) with a minimum 
detection limit of 1.9µg/L.  IGFBP-3 concentrations measured using a commercial Quantikine 
ELISA kit (R&D Systems Europe Ltd, Abingdon, UK) with a minimum limit of detection 
limit of 0.04µg/L.  All samples were analysed in duplicate and the mean value was calculated.  
The inter- and intra-assay variabilities were consistently less than 10%. 
Leptin was quantified by an in-house radio-immunoassay, which has been described 
and validated elsewhere19. 
The GPS was constructed as previously described7.  Briefly, patients with both an 
elevated C-reactive protein (>10mg/l) and hypoalbuminaemia (<35g/l) were allocated a score 
of 2.  Patients with only one of these biochemical abnormalities were allocated a score of 1.  
Patients in whom neither of these abnormalities was present were allocated a score of 0.  
Recently, however, this has been modified based on evidence that hypoalbuminaemia, 
without an elevated C-reactive protein concentration, had no significant association with 
cancer specific survival.  Therefore, patients with an elevated C-reactive protein were 
assigned a modified GPS score (mGPS) of 1 or 2 depending on the absence or presence of 
hypoalbuminaemia20.  The rationale for the development of the GPS has been described 
previously8 and the prognostic value of the combination of C-reactive protein and albumin 
has validated in a variety of common solid tumours21. 
 
Statistical Analysis 
Grouping of the variables age, BMI, ECOG-ps, haemoglobin and white cell count was 
carried out using standard thresholds22-24.  Survival analysis of the variables was performed 
using the Cox proportional hazard model.  Deaths up to the end of February 2008 were 
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included in the analysis.  Multivariate survival analysis, including all significant covariates 
(P<0.05 to account for multiple comparisons) was performed using a stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival.  To remove a variable from the model, the corresponding P-value 
had to be greater than 0.05.  The relationships between the mGPS and other variables were 
analysed using the Mantel–Haenszel (X2) test for trend as appropriate.  Analysis was 
performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
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Results  
The characteristics of the 56 patients with inoperable NSCLC are shown in Table 1.  
The patients were predominantly male (61%), over 60 years old (80%) with advanced (stage 
III or IV) disease (98%).  The majority of patients had a BMI >20 (84%), had an ECOG-ps of 
0 or 1 (79%), had a haemoglobin (59%) and white cell count (79%) in the reference range.   
The minimum follow-up was 48 months and the median follow-up of the survivors 
was 54 months.  During this period, 43 (77%) died of their cancer.  On univariate analysis, a 
low BMI (p<0.05), poor ECOG-ps (p<0.05) and low haemoglobin (p<0.05) were associated 
with cancer specific survival.  In contrast, increasing TNM stage (p<0.05), white cell count 
(p<0.05) and mGPS (p<0.05) were associated with cancer specific survival.  There was no 
association between age, sex, treatment, IGF-1, IGFBP-3, IGF-1:IGFBP-3 ratio, or leptin and 
cancer specific survival.  On multivariate analysis of significant variables, only increasing 
white cell count (p<0.05), TNM stage (p<0.005) and mGPS (p<0.001) retained statistical 
significance.  
 The relationship between the mGPS and the clinicopathological characteristics of the 
patients with inoperable NSCLC are shown in Table 2).  Age, sex, BMI, stage, ECOG-ps, 
white cell count, IGF-1, leptin and treatment were similar across the mGPS groups.  With an 
increasing mGPS concentrations of haemoglobin (p<0.005) and IGFBP-3 (p<0.05) decreased.  
Also, there was a trend towards an increase in the IGF-1: IGFBP-3 ratio (p<0.1) as mGPS 
increased.  
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Discussion 
In the present study there was no significant association between IGF-1, IGFBP-3, 
IGF-1:IGFBP-3 ratio, or leptin and survival.  In contrast, the inflammation based prognostic 
score the mGPS, was independently associated with survival.  Also with an increasing mGPS, 
IGFBP-3 concentrations were significantly decreased whereas there was no significant 
association with either IGF-1 or leptin.  Taken together these results would suggest that 
anabolism (IGF-1 axis) plays a minor role in the relationship between nutritional and 
functional decline, systemic inflammation and poor survival in patients with inoperable 
NSCLC. 
Recently there has been considerable speculation regarding the involvement of the 
IGF-1 axis in the aetiology of lean tissue loss in cancer25,26.  IGF-1 is the downstream 
mediator of growth hormone (GH) action thus representing a key pathway in anabolism in 
health.  Indeed, several studies have reported a reduction in circulating concentrations of IGF-
1 in malignant disease, which may also have been be associated with nutritional decline15,27,28.  
In the present study, the median weight loss in patients was 1% which may explain why 
concentrations of IGF-1 were not significantly altered.  The present study did not address the 
possibility of receptor resistance to IGF-1 action, and the possibility remains that ineffective 
IGF-1 action contributes towards cancer cachexia.   
In the present study, the circulating concentrations of IGF-1 and IGFBP-3 of patients 
with inoperable NSCLC were not associated with body mass index or survival.  However, 
when grouped according to mGPS score, levels of IGFBP-3 were significantly lower in 
patients with a higher mGPS.  As IGFBP-3 binds to and sequesters IGF-1, reducing its 
bioactivity but prolonging its half-life, low concentrations of IGFBP-3 may contribute to an 
enhanced but short-lived action of IGF-1 in the patient.  Also, Crown and co-workers17 
reported that circulating concentrations of IGF-1 and IGFBP-3 were unchanged in 30 patients 
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with NSCLC.  They reported a negative correlation between the ratio of intact /total IGFBP-3 
and the initial body weight of the cancer patients, suggesting that less IGFBP-3 proteolytic 
activity was associated with more weight loss, possibly by maintaining a high IGF-1 binding 
capacity, and reducing IGF-1 bioavailability to the tissues.  However, it is possible the 
reduced concentrations of IGFBP-3 merely reflect the reduction in hepatic protein synthesis, 
following a systemic insult of this nature. IGFBP-3 is also known to inhibit cell growth 
independently of IGF-1 and may have a role in mediating apoptosis29.  These results suggest 
that major alterations in the IGF-1 axis do not occur prior to significant weight loss or as a 
result of the systemic inflammatory response. Moreover, the present study questions whether 
IGF-1 axis has any association with prognosis in patients with inoperable NSCLC. 
 It is increasingly recognised that systemic inflammation is an important factor in the 
progressive loss of lean tissue in cancer patients4,6,30.  In light of the above studies on the IGF-
1 axis15,17 it is possible that the increased systemic inflammation-driven demand for amino 
acids for increased hepatic synthesis of acute phase proteins31, maintenance of albumin 
synthesis32 and increased glucose production33 is the main factor in the progressive loss of 
lean tissue in cancer patients.  This is consistent with the evidence that moderation of the 
systemic inflammatory response is a useful approach to the management of the loss of weight 
and lean tissue in cancer patients34,35. 
The main limitations of the present study were that small numbers of patients were 
studied and only baseline measurements were included in the analysis.  Furthermore, the 
patient recruitment from an outpatient clinic may have biased the population towards those 
with less weight loss and a better performance status since those patients with more weight 
loss and poorer performance status are less likely to attend such clinics.  Therefore, 
longitudinal measurements of the relationship between weight loss, IGF-1, IGF-BP3 and the 
systemic inflammatory response during the progression of the disease would have been of 
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interest to corroborate the cross sectional results.  Nevertheless, the present baseline data, at 
diagnosis and with mature survival follow-up, are important as they have clinical relevance 
since they identify patients who may benefit from early nutritional or therapeutic intervention. 
In summary, the results of this study suggest that anabolism (IGF-1 axis) does not play 
a significant role in the relationship between nutritional and functional decline, systemic 
inflammation and poor survival in patients with inoperable NSCLC. 
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Table 1.  Prognostic factors of patients with NSCLC. 
 
 Patients 
(n= 56) 
Hazard ratio 
(95% CI) 
P- value 
 
Age (<60/ >60 years) 
 
11/ 45 
 
0.792 (0.38-1.66) 
 
0.536 
Sex (M/F) 34 / 22 1.13 (0.61-2.08) 0.704 
BMI  (>20/ <20) 47/ 9 2.33 (1.07-5.08) 0.034 
Stage (II/ III/ IV) 1/ 29/ 26 1.81 (1.02-3.20) 0.042 
ECOG-ps (0/ 1/ 2) 20/ 24/ 12 1.62 (1.07-2.44) 0.021 
Haemoglobin (>12/ <12 g/dl) 33/ 22 1.87 (1.01-3.46) 0.047 
White cell count (<11/ >11 109/l) 44/ 12 2.42 (1.21-4.87) 0.013 
    
IGF-I (µg/L) tertiles 102.01 (16.00-310.00)* 1.35 (0.93-1.95) 0.116 
IGFBP-3 (ng/mL) tertiles 
 
2147.38 (58.92-4881.09)* 1.27 (0.87-1.87) 0.215 
IGF-I:IGFBP-3 tertiles 0.04 (0.02-0.27)* 1.02 (0.71-1.47) 0.913 
Leptin (ug/l) tertiles 8.35 (1.00-103.00)* 0.78 (0.54-1.13) 0.194 
    
Treatment (active/ palliative) 46/ 10 0.93 (0.41-2.09) 0.862 
mGPS (0/ 1/ 2) 
 
19/ 31/ 6 2.10 (1.30- 3.40) 0.002 
 
*Median (range) 
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Table 2.  Characteristics of patients with NSCLC grouped according to mGPS. 
 
 mGPS 0 
(n=19) 
mGPS 1 
(n=31) 
mGPS 2 
(n=6) 
P- value 
Age (<60/ >60 years) 3/ 16 7/ 24 1/ 5 0.768 
Sex (M/ F) 12/ 7 17/ 14 5/ 1 0.699 
BMI  (>20/ <20) 17/ 2 26/ 5 4/ 2 0.229 
Stage (II/ III/ IV) 0/ 8/ 11 1/ 18/ 12 0/ 3/ 3 0.383 
ECOG-ps (0/ 1/ 2) 9/ 8/ 2 9/ 14/ 8 2/ 2/ 2 0.143 
Haemoglobin (>12/ <12 g/dl) 16/ 3 16/ 14 1/ 5 0.002 
White cell count (<11/ >11 109/l) 15/ 4 26/ 5 3/ 3 0.358 
     
IGF-I (ug/L) tertiles 7/ 9/ 3 10/ 7/ 14 1/ 4/ 1 0.292 
IGFBP-3 (ng/mL) tertiles 2/ 8/ 9 13/ 11/ 7 3/ 1/ 2 0.035 
IGF-I:IGFBP-3 tertiles 10/ 5/ 4 5/ 12/ 14 3/ 2/ 1 0.271 
Leptin (ug/l) tertiles 
 
6/ 6/ 6 7/ 12/ 12 5/ 0/ 0 0.174 
Treatment (active/ palliative) 16/ 3 25/ 6 5/ 1 0.859 
 
 
